Medly is the first telemonitoring system to be designated a Class II medical device by Health Canada. Inside University Health Network, it has proven to cut rehospitalizations by 50% and all-cause admissions by 24% for people with heart failure.
Medly is being deployed in specialty cardiac centres and primary care clinics across Ontario. Medly Therapeutics is working with institutions to see how the technology can fit in their workflows.
Any interested clinicians may reach out to the Medly team to learn more about the successful model, best practices, and details on implementation.